Esomefol SL 75mg/40mg Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75mg and Esomeprazole 40mg, designed for sustained release administration. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties, effectively enhancing gastrointestinal motility and providing relief from symptoms associated with functional dyspepsia, gastroesophageal reflux disease (GERD), and delayed gastric emptying. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby promoting mucosal healing and reducing acid-related irritation. The synergistic action of these agents addresses both motility disorders and acid hypersecretion, making Esomefol SL particularly beneficial in managing conditions such as erosive esophagitis, non-ulcer dyspepsia, and GERD with associated motility disturbances. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance and clinical efficacy. Esomefol SL should be administered under medical supervision, with consideration of contraindications such as hypersensitivity to components, and caution in patients with renal or hepatic impairment. Adverse effects may include headache, dizziness, gastrointestinal disturbances, and extrapyramidal symptoms, necessitating periodic monitoring during therapy.